Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz2. fázis

A study to test if SRSD107 prevents venous thromboembolism events and how safe it is

A legfontosabb adatok

Ki végzi
Sirius Therapeutics Inc.
Hol
Bulgária, Csehország, Lengyelország, Lettország, Litvánia és Magyarország39 helyszín, 6 országbanVálassz országot a helyszínekhez
Állapot
Fut, nem toboroz
Fázis
2. fázis
Résztvevők
300 fő, tervezett
Kezdés
2025. aug. 7.
Várható befejezés
2026. dec. 7.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2026. augusztus 28.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 18 feltétel megnézéseKevesebb

Ki vehet részt

  • Able to provide written informed consent before any study assessment is performed
  • Male and female subjects, of any race, between 60 and 80 years of age, inclusive. Female subjects should not be of child-bearing potential.An interim analysis of safety data will be conducted by the SSC after 50 subjects complete 12 weeks of follow-up; pending SSC approval following this analysis, enrollment of subjects between 81 and 85 years of age (inclusive) will be allowed
  • Body mass index between 18.0 and 38.0 kg/m2, inclusive
  • Eligible to undergo elective primary unilateral TKA under general anesthesia
  • Willing to comply with study requirements including taking study drug at least 28 days prior to TKA, clinic visits, and venography at 10-14 days post TKA
  • Activated partial thromboplastin time (aPTT), prothrombin time (PT), and international normalized ratio (INR) within the normal reference range at screening
  • Males will agree to use contraception

Ki nem vehet részt

  • Active bleeding requiring medical or surgical intervention within 4 weeks prior to screening
  • Myocardial infarction, stroke (hemorrhagic, ischemic or mixed), transient ischemic attack, systemic embolism, valvular thrombosis, or splanchnic thrombosis in the 6 months prior to screening, or any lifetime history of DVT or PE
  • Positive test for human immunodeficiency virus (HIV) (CD4+>200/mm3 can be included), positive hepatitis B surface antigen, and/or active hepatitis C (by HCV RNA testing) at screening
  • Known bleeding disorder, history of increased bleeding tendency (e.g., history of bleeding diathesis, known active gastrointestinal lesions such as angiodysplasia or an endoscopically verified gastrointestinal ulcer or a history of gastrointestinal bleeding within the past year) or any other condition that in the opinion of the investigator contraindicates prophylactic anticoagulation
  • History of intracranial, intraspinal, or intraocular bleeding
  • Evidence of active cancer, or a history of malignancy, within 2 years prior to screening. Nonmelanoma skin cancer, curatively treated localized breast or prostate cancer, or other carcinoma in situ are not exclusionary, providing that they did not require systemic chemotherapy (hormonal therapy allowed) and are considered cured
  • Platelet count < 100,000/m3 at screening or a history of heparin-induced thrombocytopenia
  • Estimated (by Modification of Diet in Renal Disease [MDRD]) glomerular filtration rate (eGFR) < 45 mL/min/1.73m2
  • Liver dysfunction (alanine aminotransaminase or aspartate aminotransferase >1.5× upper limit of normal [ULN] or total bilirubin > ULN), liver cirrhosis (Child-Pugh class B and C excluded; Child-Pugh A allowed), history of hepatic encephalopathy, esophageal varices, or portocaval shunt. Subjects with Gilbert’s syndrome are allowed to participate
  • Clinically significant anemia (hemoglobin <10 g/dL) at screening
  • Uncontrolled blood pressure as defined by a systolic blood pressure ≥ 180 mmHg and/or a diastolic blood pressure ≥ 110 mmHg at the time of screening

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

6 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

To evaluate the efficacy of SRSD107 in subjects undergoing elective, primary, unilateral total knee arthroplasty (TKA) comparing SRSD107 to enoxaparin

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
A Multicenter, Randomized, Open-Label, Blinded Endpoint Evaluation, Active-Controlled Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing Elective Primary Unilateral Total Knee Arthroplasty.
A regiszteradat frissítve
2026. augusztus 28.